Numbers

The Numbers

Novonesis is the world's largest industrial-biosolutions company — enzymes, probiotics and microbial cultures sold into food, feed, bioenergy, household care and human health. Since the Novozymes/Chr. Hansen combination closed on 29 January 2024 and the Feed Enzyme Alliance (DSM-Firmenich stake) buyout in 2025, the P&L has three distinct regimes: a high-margin standalone Novozymes (2020-2023, ~33% adj. EBITDA margin on ~EUR 2bn sales), a merger-reset 2024 (~EUR 3.8bn reported, goodwill ballooning to EUR 5.6bn, a one-off PPA drag), and a cleaner 2025 (EUR 4.16bn sales, 37.1% adj. EBITDA margin, 7% organic growth). The stock now trades at roughly 41x IFRS trailing EPS and 26x adjusted-ex-PPA EPS against a consensus 2026 P/E of 33x — a structural quality premium hinged on the adjusted EBITDA margin holding 37-38% while capex steps up to 12-14% of sales for the 2030 GROW plan. That margin trajectory, and whether the Agriculture/Energy/Tech unit re-accelerates from Q4's 0% organic growth, is the single lever most likely to rerate or derate this name.

All financial statement figures are in EUR (reporting currency); share price and dividends are in DKK (listing currency, Nasdaq Copenhagen). Pro-forma 2024 numbers treat Chr. Hansen as if owned from Jan 1, 2024.

Snapshot

1. Is this a well-run business that will still be around in 10 years?

Novonesis scores well on the durability questions: a 37% adjusted EBITDA margin, mid-single-digit organic growth, a 59% adjusted gross margin and NIBD/EBITDA comfortably under 2x. The catch is ROIC: including the EUR 5.6bn of goodwill from Chr. Hansen, adjusted ROIC is just 5.6%. Excluding goodwill it recovers to 10.1% — not great, not disastrous — and the 2030 strategy explicitly targets organic ROIC expansion as cost and revenue synergies annualise.

2. Revenue & earnings power — 5-year view

Only 5 years of clean IFRS history are available; Novonesis as a reporting entity was created on 29-Jan-2024. Pre-2024 figures reflect Novozymes standalone, so year-on-year comparability is limited. We show both IFRS-reported and key pro-forma markers for context.

Revenue nearly doubled in 2024 from consolidating Chr. Hansen, and 2025 is the first clean year under the combined perimeter — 7% organic growth plus merger synergies driving EBIT ex-special items to EUR 883m, a new high.

The headline is not a fall in the true margin — adjusted EBITDA margin expanded from 33.2% in 2023 to 37.1% in 2025 — but an optical drag from IFRS 3 purchase-price-allocation amortisation. Reported EBIT margin dropped from 26% to 17% in 2024 on PPA step-ups, then recovered to 21% in 2025 as synergies annualised.

Quarterly direction (last 8 quarters, IFRS)

3. Cash generation — are the earnings real?

Cash conversion is unusually clean. Operating cash flow of EUR 1,222m in 2025 was 2.1x reported net profit — driven by the non-cash PPA amortisation that suppresses reported earnings. On a 5-year trailing basis, cumulative OpCF is EUR 3.88bn vs cumulative net profit of EUR 2.22bn, a CFO/NI ratio of 175%. FCF before acquisitions rose 16% y/y to EUR 770m despite capex stepping up to 11.3% of sales from 9.4%.

4. Capital allocation — last 5 years

Capital allocation is disciplined but has pivoted hard to growth: capex is rising toward 12-14% of sales for the 2030 GROW plan (production-capacity expansion), 2025 absorbed EUR 1.52bn in net acquisitions (buying out DSM-Firmenich's Feed Enzyme Alliance stake), dividends of EUR 403m were paid (DKK 6.50 per share for 2025 vs DKK 6.20 in 2024), and the group re-opened share buybacks at modest scale (EUR 100m). With NIBD/EBITDA at 1.9x vs target ~1.7x, buybacks are likely capped until leverage eases.

5. Balance sheet — goodwill, debt and the shape of the merger

The balance-sheet story is simple: goodwill of EUR 5.6bn now represents 34% of total assets — the Chr. Hansen transaction set the bar for what Novonesis must out-earn. Net debt jumped to EUR 2.73bn in 2025 on the Feed Enzyme Alliance acquisition, but NIBD/EBITDA at 1.9x remains below the 2x the market typically treats as an investment-grade ceiling, and management has guided leverage back to ~1.7x by year-end 2026. The EUR 1.7bn bond issue in March 2026 replaces the bridge facility.

6. Valuation — what the market is paying

The stock peaked at DKK 501 at end-2021, de-rated sharply through 2022 on merger-arb and macro concerns, then traded sideways through the Chr. Hansen integration. Today's DKK 382 is ~24% off the 2021 peak despite revenue roughly doubling — the rerating work is still ahead.

Depending on which earnings line you trust, Novonesis trades at 26x (adjusted ex-PPA) to 41x (IFRS) trailing. The forward 2026 consensus P/E of 33x compares to MarketScreener's sector median (specialty chemicals) EV/EBITDA of ~7.3x; Novonesis trades at ~20x trailing EV/EBITDA — a structural premium consistent with its 37% margins, mid-single-digit organic growth, and the regulatory moat of its enzyme IP and fermentation manufacturing base.

7. Peer comparison — biosolutions / industrial chemistry

Peer multiples are approximate TTM estimates from recent sell-side and MarketScreener snapshots; used only for relative positioning.

Novonesis is the highest-margin, fastest-growing integrated biosolutions pure-play in the set. Givaudan trades richer on P/E (32x vs 26x) but has half the EBITDA-growth profile and a similar margin; IFF and DSM-Firmenich trade at lower multiples because both carry execution risk from prior mega-mergers that have yet to recover their pre-deal earnings. The ~20x EV/EBITDA Novonesis commands is the tax for being the cleanest name in a messy industry.

8. Fair value — bear / base / bull

The base case of ~DKK 455 sits on top of the 17-analyst consensus average and implies the 2026 adjusted EBITDA margin guide of 37-38% is delivered. The bull case of DKK 545 matches SEB's current target and requires merger synergies to annualise into 2027 EPS, capex ratios to start declining, and ROIC ex-goodwill to move toward the mid-teens. The bear case of DKK 320 would require organic growth to fall below 4% while capex stays elevated — not a remote scenario if the Q4 Planetary Health weakness persists.

Bottom line

The numbers confirm that Novonesis is a high-quality franchise: 37% adjusted EBITDA margins, 175% five-year cumulative cash conversion, single-digit organic growth with pricing, and a moat rooted in enzyme IP and fermentation manufacturing. They contradict the view that the Chr. Hansen merger has already paid for itself — adjusted ROIC including goodwill is still only 5.6%, and the EUR 5.6bn goodwill block means any lasting underperformance would invite impairment risk. What to watch in 2026: whether Agriculture, Energy & Tech recovers above the 4% organic run-rate shown in Q4; whether capex peaks below the 14% of sales upper guide; and whether management delivers the promised 37-38% adjusted EBITDA margin even with the USD headwind that is only 72% hedged.